For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $591.99 in the prior trading day, Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) closed at $595.68, up 0.62%. In other words, the price has increased by $0.62 from its previous closing price. On the day, 0.9 million shares were traded. REGN stock price reached its highest trading level at $600.62 during the session, while it also had its lowest trading level at $588.6734.
Ratios:
Our goal is to gain a better understanding of REGN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.43 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.38. For the most recent quarter (mrq), Quick Ratio is recorded 3.72 and its Current Ratio is at 4.60. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Rothschild & Co Redburn on August 14, 2025, initiated with a Buy rating and assigned the stock a target price of $890.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 01 ’24 when McCourt Marion sold 1,000 shares for $844.61 per share. The transaction valued at 844,610 led to the insider holds 12,931 shares of the business.
MARION E MCCOURT bought 1,000 shares of REGN for $844,610 on Nov 01 ’24. On Oct 01 ’24, another insider, RYAN ARTHUR F, who serves as the Director of the company, sold 100 shares for $1048.78 each. As a result, the insider received 104,878 and left with 17,582 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 63134597120 and an Enterprise Value of 57000034304. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.01, and their Forward P/E ratio for the next fiscal year is 14.82. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 11.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.44 while its Price-to-Book (P/B) ratio in mrq is 2.12. Its current Enterprise Value per Revenue stands at 4.01 whereas that against EBITDA is 12.761.
Stock Price History:
The Beta on a monthly basis for REGN is 0.32, which has changed by -0.43050534 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $1154.56, while it has fallen to a 52-week low of $476.49. The 50-Day Moving Average of the stock is 4.86%, while the 200-Day Moving Average is calculated to be -3.45%.
Shares Statistics:
The stock has traded on average 1.01M shares per day over the past 3-months and 1019370 shares per day over the last 10 days, according to various share statistics. A total of 104.60M shares are outstanding, with a floating share count of 102.13M. Insiders hold about 3.64% of the company’s shares, while institutions hold 86.27% stake in the company. Shares short for REGN as of 1756425600 were 2827689 with a Short Ratio of 2.81, compared to 1753920000 on 2291886. Therefore, it implies a Short% of Shares Outstanding of 2827689 and a Short% of Float of 2.8199999.
Earnings Estimates
Current recommendations for the stock of the company come from 19.0 analysts. The consensus estimate for the next quarter is $9.11, with high estimates of $11.38 and low estimates of $6.65.
Analysts are recommending an EPS of between $43.33 and $35.0 for the fiscal current year, implying an average EPS of $39.41. EPS for the following year is $35.98, with 11.0 analysts recommending between $46.12 and $26.77.
Revenue Estimates
19 analysts predict $3.57B in revenue for the current quarter. It ranges from a high estimate of $3.8B to a low estimate of $3.39B. As of the current estimate, Regeneron Pharmaceuticals, Inc’s year-ago sales were $3.72BFor the next quarter, 19 analysts are estimating revenue of $3.61B. There is a high estimate of $4.05B for the next quarter, whereas the lowest estimate is $3.37B.
A total of 24 analysts have provided revenue estimates for REGN’s current fiscal year. The highest revenue estimate was $14.55B, while the lowest revenue estimate was $13.57B, resulting in an average revenue estimate of $13.89B. In the same quarter a year ago, actual revenue was $14.2BBased on 24 analysts’ estimates, the company’s revenue will be $14.52B in the next fiscal year. The high estimate is $15.48B and the low estimate is $13.03B.
